SRZN Surrozen, Inc.
$29.53▲ +8.25%
Healthcare
Other
After hours
$29.53▲ +0.00%
Oct 27, 4:41 PM ET
Volume 431.6K
Avg Volume (10D) 507.4K
Key Metrics & Fundamentals
Market Cap
$516.63M
P/E Ratio
–
Div Yield
0.00%
52W Range
11.39 - 37.83
% vs 50 MA
23.24%
% vs 200 MA
18.36%
RSI-14
60.7
MACD Histogram
+0.1300
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$7.43M
Gross Rev
$5.00M
Gross Profit
$5.00M
EBITDA
-$49.57M
COGS
–
Operating Exp
$15.37M
Operating Income
-$10.37M
EBIT
-$10.37M
Pretax Income
$50.18M
Net Income
$50.18M
EPS (Diluted)
-0.41
Price & Volume History
Loading chart…
Recent News
Surrozen Raises $95.1 Million in Private Placement
MT Newswires · Oct 20, 2026 5:24 PM ET
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
GlobeNewswire · Oct 20, 2026 4:59 PM ET
Top Biotech Stock: Guggenheim Names Surrozen as Best Pick
Investing.com · Oct 15, 2026 2:22 PM ET
Surrozen secures FDA clearance for SZN-8141 clinical trial
Clinical Trials Arena · Oct 5, 2026 6:51 AM ET
Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance
MT Newswires · Oct 2, 2026 8:56 AM ET
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
GlobeNewswire · Oct 2, 2026 8:00 AM ET
Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema
MT Newswires · Sep 8, 2026 10:40 AM ET
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
GlobeNewswire · Sep 8, 2026 8:30 AM ET
Surrozen to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire · Sep 2, 2026 4:05 PM ET
William Blair Initiates Surrozen at Outperform
MT Newswires · Aug 20, 2026 6:54 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SRZN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.